We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA expressed concerns about their clinical validity, noting that it was “unaware of data establishing the relationships between the genotypes assessed…and assertions regarding drug response for multiple drugs. Read More
The FDA is also seeking $76 million to support drug compounding activities and develop new regulations to improve the quality of products from outsourcing facilities. Read More